pipeline
Saviximab®(Anti-SARS-CoV-2) Nanobody
SARS-CoV-2
| Optimization | Pre-clinical | ADMET/CMC | Ph Ⅰ | Ph Ⅱ |
|---|---|---|---|---|
|
IV
|
||||
Shaperon has successfully developed Saviximab®, a single domain neutralizing antibody for SARS-CoV-2.
Saviximab® shows excellent therapeutic effects in the hamster model infected with the SARS-CoV-2 virus by suppressing the proliferation of SARS-CoV-2 virus in the lung tissue and reducing inflammation and swelling.
